{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GS", "query": { "condition": "GS" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GS&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T09:29:54.435Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01271790", "title": "A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Tegobuvir (GS-9190)", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "Pegasys®", "type": "BIOLOGICAL" }, { "name": "Copegus®", "type": "DRUG" }, { "name": "Tegobuvir placebo", "type": "DRUG" }, { "name": "GS-9451 placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 245, "start_date": "2010-10", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-07-23T09:29:54.435Z", "location_count": 85, "location_summary": "Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01271790" }, { "nct_id": "NCT01353248", "title": "GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "Tegobuvir", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "ribavirin tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 141, "start_date": "2011-05", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2013-12-20", "last_synced_at": "2026-07-23T09:29:54.435Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Anaheim, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01353248" }, { "nct_id": "NCT00874796", "title": "Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HCV Infection" ], "interventions": [ { "name": "GS-9450", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 307, "start_date": "2009-05", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2014-02-04", "last_synced_at": "2026-07-23T09:29:54.435Z", "location_count": 51, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 48 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00874796" }, { "nct_id": "NCT00195039", "title": "Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 47, "start_date": "2004-08", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2017-10-05", "last_synced_at": "2026-07-23T09:29:54.435Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00195039" }, { "nct_id": "NCT00081172", "title": "Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "lutetium Lu 177 monoclonal antibody J591", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": "2004-01", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-07-23T09:29:54.435Z", "location_count": 3, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081172" }, { "nct_id": "NCT00743795", "title": "Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HCV Infection" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "GS-9190", "type": "DRUG" }, { "name": "Peginterferon Alfa 2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 252, "start_date": "2008-10", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2013-11-05", "last_synced_at": "2026-07-23T09:29:54.435Z", "location_count": 48, "location_summary": "Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Clemente", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00743795" }, { "nct_id": "NCT00936715", "title": "Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 24, "start_date": "2009-08", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-06-02", "last_synced_at": "2026-07-23T09:29:54.435Z", "location_count": 4, "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00936715" }, { "nct_id": "NCT01539291", "title": "Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2012-10-03", "completion_date": "2018-06-29", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-07-23T09:29:54.435Z", "location_count": 30, "location_summary": "Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 24 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01539291" }, { "nct_id": "NCT01796470", "title": "Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Diffuse Large B-cell Lymphoma", "Indolent Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Entospletinib", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2013-06-20", "completion_date": "2016-12-22", "has_results": true, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-07-23T09:29:54.435Z", "location_count": 13, "location_summary": "La Jolla, California • Long Beach, California • Oxnard, California + 10 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01796470" }, { "nct_id": "NCT00740610", "title": "Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonalcoholic Steatohepatitis" ], "interventions": [ { "name": "GS-9450", "type": "DRUG" }, { "name": "GS-9450 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 124, "start_date": "2008-08", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2014-02-04", "last_synced_at": "2026-07-23T09:29:54.435Z", "location_count": 31, "location_summary": "Tucson, Arizona • Fresno, California • Fullerton, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Mateo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00740610" } ] }